DNA-targeting ruthenium(II) complexes that simultaneously induce tumor apoptosis and autophagy

Area of Science:

• Inorganic Chemistry
• Cancer Biology
• Medicinal Chemistry

Background:

• DNA damage and cell cycle regulation are crucial targets in cancer therapy.
• Ruthenium complexes are explored for their therapeutic potential in oncology.

Purpose of the Study:

• To design and synthesize novel ruthenium(II) complexes with β-carboline ligands.
• To evaluate the in vitro antitumor activity of these complexes.
• To elucidate the mechanisms underlying their anticancer effects.

Main Methods:

• Synthesis of two ruthenium(II) complexes: Ru1 and Ru2.
• In vitro assessment of antitumor activity against cancer cells.
• Investigation of DNA binding, reactive oxygen species (ROS) generation, cell cycle arrest, autophagy, and apoptosis induction.

Main Results:

• Both Ru1 and Ru2 demonstrated significant in vitro antitumor activity.
• The complexes were found to bind to nuclear DNA and induce DNA damage via ROS generation.
• Both complexes induced S-phase cell cycle arrest, with Ru1 also triggering autophagy.
• These events collectively led to tumor cell apoptosis.

Conclusions:

• The synthesized ruthenium complexes exhibit potent anticancer effects through DNA targeting and induction of cell death pathways.
• These findings present a novel therapeutic strategy for cancer treatment utilizing DNA-damaging ruthenium complexes.
• Further research into these complexes could lead to new cancer therapies.